Related Experiment Video
Updated: Jun 6, 2026

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
Published on: April 3, 2018
[Construction of an oncolytic adenovirus expressing small hairpin RNA and targeting the SATB1 gene]
Li-Jun Mao1, Jun-Nian Zheng, Wang Li
1Department of Urology, The Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu 221002, China.
Objective:
To construct an oncolytic adenovirus with the DD3 promoter regulation, expressing small hairpin RNA and targeting the SATB1 gene (SATBI-shRNA), and to evaluate its potential for inhibiting the growth of human prostatic carcinoma cells (LNCaP) in vitro.
Methods:
SATB1-shRNA expression cassettes containing the H1 promoter were produced by PCR from pSilencer3. 1-SATB1 and inserted into the pZD55 vector, and the recombinant plasmid pZD55-SATB1-shRNA was constructed, pZD55SATB1-shRNA and pZXC2-DD3-E1A were digested with EcoRV and Xba I , and the obtained expression cassettes linked each other to construct the recombinant plasmid pDD3-ZD55-SATB1, which was cotransfected with the pBHGE3 packaging plasmids mixture into 293 cells by Effectence. The recombined adenoviruses DD3-ZD55-SATB1 were identified by PCR. Viruses were propagated on HEK293 cells and purified by standard techniques, and the functional PFU titers determined by plaque assay on 293 cells. The antitumor potential of DD3-ZD55-SATB1 to LNCaP was evaluated by the crystal violet dye method. The expression level of the E1A gene was detected by Western blot, and that of the SATB1 gene in the adenovirus-infected LNCaP cells by both Western blot and RT-PCR.
Results:
An oncolytic adenovirus expressing SATB1-shRNA with the DD3 promoter regulation, DD3-ZD55-SATB1, was constructed successfully, whose functional PFU titer was 1.2 x 10(10) PFU/ml. DD3-ZD55-SATB1 showed an obvious cytopathic effect and a selective expression of E1A in the adenovirus-infected LNCaP cells; it exhibited a high LNCaP-targetability and specific SATB1-silencing effect.
Conclusion:
The successful construction of the oncolytic adenovirus DD3-ZD55-SATB1 offers a new tool for researches on the gene therapy for human prostate cancer.
Insights
This study successfully constructed a novel oncolytic adenovirus, DD3-ZD55-SATB1, for prostate cancer gene therapy. This virus specifically targets and silences the SATB1 gene in human prostate cancer cells, showing significant potential for future treatments.
Area of Science:
- Oncolytic virotherapy
- Gene therapy
- Molecular oncology
Context:
- Prostate cancer remains a significant health concern with limited effective treatments.
- Targeting specific genes like SATB1 is a promising strategy for cancer therapy.
- Oncolytic adenoviruses offer a targeted approach for cancer cell destruction.
Purpose:
- To construct a DD3 promoter-regulated oncolytic adenovirus expressing SATB1-targeting small hairpin RNA (SATB1-shRNA).
- To evaluate the efficacy of the constructed adenovirus (DD3-ZD55-SATB1) in inhibiting human prostate cancer LNCaP cell growth in vitro.
Summary:
- A recombinant oncolytic adenovirus, DD3-ZD55-SATB1, was successfully constructed and characterized.
- The virus demonstrated selective E1A expression in LNCaP cells, leading to cytopathic effects.
- DD3-ZD55-SATB1 effectively targeted LNCaP cells and specifically silenced SATB1 gene expression.
Impact:
- The successful development of DD3-ZD55-SATB1 provides a novel tool for prostate cancer gene therapy research.
- This oncolytic adenovirus shows potential for targeted SATB1 gene silencing in prostate cancer treatment.
- Further research may lead to new therapeutic strategies for human prostate cancer.
Related Concept Videos
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Subviral Agents
